Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity. This triggers degradation of specific transcription factors, leading to anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that suppress malignant cell growth.

The prescribed dose of Lenalidomide Grindeks is determined by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosing regimens are individualized and should follow the prescriber’s instructions.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended during breastfeeding because it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism of action compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration and can be combined with other agents, whereas alternatives may require intravenous infusion or have different safety profiles.

Store Lenalidomide Grindeks at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lenalidomide Grindeks is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact schedule (e.g., daily or on specific days of a cycle) is individualized based on the treatment plan.

Serious risks include venous thromboembolism, severe neutropenia or infections, and the potential for secondary primary malignancies. Patients should be monitored closely for signs of blood clots, infections, and any unexpected symptoms.

Lenalidomide Grindeks should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections or certain contraindicated drug interactions. The prescriber will assess suitability before initiating therapy.